DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC to develop a series of next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:DXCM
CUSIP25213110
Phone858-200-0200
Debt
Debt-to-Equity Ratio0.69
Current Ratio4.89
Quick Ratio4.62
Price-To-Earnings
Trailing P/E Ratio-240.52
Forward P/E Ratio-296.81
P/E GrowthN/A
Sales & Book Value
Annual Sales$718.50 million
Price / Sales17.16
Cash FlowN/A
Price / CashN/A
Book Value$4.83 per share
Price / Book28.88
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-50,200,000.00
Net Margins-0.65%
Return on Equity-7.45%
Return on Assets-3.48%
Miscellaneous
Employees2,990
Outstanding Shares88,360,000
Market Cap$12.32 billion
DexCom (NASDAQ:DXCM) Frequently Asked Questions
What is DexCom's stock symbol?
DexCom trades on the NASDAQ under the ticker symbol "DXCM."
How were DexCom's earnings last quarter?
DexCom, Inc. (NASDAQ:DXCM) announced its quarterly earnings results on Wednesday, August, 1st. The medical device company reported ($0.10) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.18) by $0.08. The medical device company earned $242.50 million during the quarter, compared to the consensus estimate of $205.81 million. DexCom had a negative return on equity of 7.45% and a negative net margin of 0.65%. The firm's quarterly revenue was up 42.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.16) earnings per share. View DexCom's Earnings History.
When is DexCom's next earnings date?
What price target have analysts set for DXCM?
22 brokers have issued twelve-month price targets for DexCom's stock. Their predictions range from $40.00 to $160.00. On average, they anticipate DexCom's stock price to reach $111.6389 in the next twelve months. This suggests that the stock has a possible downside of 20.0%. View Analyst Price Targets for DexCom.
What is the consensus analysts' recommendation for DexCom?
22 Wall Street analysts have issued "buy," "hold," and "sell" ratings for DexCom in the last year. There are currently 1 sell rating, 6 hold ratings and 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for DexCom.
What are Wall Street analysts saying about DexCom stock?
Here are some recent quotes from research analysts about DexCom stock:
- 1. Stephens analysts commented, "We rate uniQure Overweight. uniQure focuses on the development of gene therapy products for patients suffering from severe genetic diseases. uniQure is in Phase 3 development for the treatment of hemophilia B with AMT-061, and has additional preclinical programs for Huntington’s disease, hemophilia A and cardiovascular disease." (8/23/2018)
- 2. According to Zacks Investment Research, "Dexcom’s is well positioned in the MedTech space, courtesy of solid contribution from Sensor revenues, Transmitter revenues and Receiver revenues in the last few quarters. The glucose monitoring market represents significant commercial opportunity for DexCom. The company’s solid foothold in the international markets, especially Germany, broad spectrum of products and strategic collaborations, are promising. On the flip side, Dexcom’s share price movement in the past year has been unimpressive. Cutthroat competition in the market for blood & glucose monitoring devices is a headwind for DexCom at the moment. We believe the company’s margins will continue to be under pressure in the coming quarters, owing to high product development costs and rising expenditures on research & development. Lower expected margins on transmitter sales are also a cause of concern." (3/16/2018)
Who are some of DexCom's key competitors?
Some companies that are related to DexCom include Baxter International (BAX), FRESENIUS SE &/S (FSNUY), ABIOMED (ABMD), ResMed (RMD), Teleflex (TFX), Hill-Rom (HRC), Insulet (PODD), Haemonetics (HAE), ICU Medical (ICUI), Integra Lifesciences (IART), Penumbra (PEN), Globus Medical (GMED), Novocure (NVCR), Cantel Medical (CMD) and NuVasive (NUVA).
Who are DexCom's key executives?
DexCom's management team includes the folowing people:
- Mr. Kevin R. Sayer, Exec. Chairman, CEO & Pres (Age 60)
- Mr. Quentin S. Blackford, Exec. VP & CFO (Age 39)
- Mr. Steven R. Pacelli, Exec. VP of Strategy & Corp. Devel. (Age 46)
- Mr. Andrew K. Balo, Exec. VP of Clinical Affairs, Regulatory Strategies & Global Access (Age 70)
- Mr. Richard B. Doubleday, Exec. VP & Chief Commercial Officer (Age 55)
Who are DexCom's major shareholders?
DexCom's stock is owned by a variety of of institutional and retail investors. Top institutional investors include FMR LLC (8.03%), Baillie Gifford & Co. (5.90%), Morgan Stanley (5.69%), Janus Henderson Group PLC (5.03%), BlackRock Inc. (4.66%) and Brown Advisory Inc. (3.60%). Company insiders that own DexCom stock include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Jess Roper, John Lister, Jorge A Valdes, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven R Altman, Steven Robert Pacelli and Terrance H Gregg. View Institutional Ownership Trends for DexCom.
Which major investors are selling DexCom stock?
DXCM stock was sold by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Brown Advisory Inc., OppenheimerFunds Inc., Jennison Associates LLC, FMR LLC, Baillie Gifford & Co., Fred Alger Management Inc. and Massachusetts Financial Services Co. MA. Company insiders that have sold DexCom company stock in the last year include Andrew K Balo, Barbara Kahn, Donald Abbey, Eric Topol, Heather S Ace, Jacob Steven Leach, Jay S Skyler, Jeffrey Moy, Kevin R Sayer, Mark G Foletta, Nicholas Augustinos, Patrick Michael Murphy, Quentin S Blackford, Richard Doubleday, Steven Robert Pacelli and Terrance H Gregg. View Insider Buying and Selling for DexCom.
Which major investors are buying DexCom stock?
DXCM stock was acquired by a variety of institutional investors in the last quarter, including Morgan Stanley, Victory Capital Management Inc., Waddell & Reed Financial Inc., Columbus Circle Investors, Point72 Asset Management L.P., Renaissance Technologies LLC, BlackRock Inc. and Federated Investors Inc. PA. View Insider Buying and Selling for DexCom.
How do I buy shares of DexCom?
Shares of DXCM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is DexCom's stock price today?
One share of DXCM stock can currently be purchased for approximately $139.50.
How big of a company is DexCom?
DexCom has a market capitalization of $12.32 billion and generates $718.50 million in revenue each year. The medical device company earns $-50,200,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. DexCom employs 2,990 workers across the globe.
What is DexCom's official website?
How can I contact DexCom?
DexCom's mailing address is 6340 SEQUENCE DRIVE, SAN DIEGO CA, 92121. The medical device company can be reached via phone at 858-200-0200 or via email at [email protected]
MarketBeat Community Rating for DexCom (NASDAQ DXCM)
MarketBeat's community ratings are surveys of what our community members think about DexCom and other stocks. Vote "Outperform" if you believe DXCM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DXCM will underperform the S&P 500 over the long term. You may vote once every thirty days.
